Hexagon Nutrition IPO
Market Sentiment
IPO Details
IPO Reservation
Market Lot Size
Financial Analysis
| Metric | 2023 | 2024 | 2025 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 281.65 | 304.62 | 331.29 | 275.57 |
| Expense | 267.02 | 285.48 | 296.78 | 239.83 |
| Profit (PAT) | 5.82 | 12.21 | 24.38 | 27.03 |
| Total Assets | 288.90 | 250.54 | 261.36 | 327.60 |
| Company | P/E | EPS |
|---|---|---|
| Zydus Wellness Limited | 46.22 | 10.90 |
| Nestlé India Limited | 88.86 | 16.63 |
Promoters: Arun Purushottam Kelkar, Subhash Purushottam Kelkar, Vikram Arun Kelkar and Nikhil Arun Kelkar
| Shareholding | No. of Shares | Holding % |
|---|---|---|
| Promoter Holding Pre Issue | 12,29,18,109 | 89.41% |
| Promoter Holding Post Issue | 12,29,18,109 | 64.29% |
Strengths & Risks
- Heavily oversubscribed — 53.5x overall (so far).
- Strong institutional (QIB) demand — 19.8x.
- Low leverage — debt/equity of 0.14.
No major red flags in the available data.
Auto-generated from live GMP, subscription, valuation and financial data. Informational only — not investment advice. Always read the RHP before applying.
Company Information
Hexagon Nutrition Limited, founded in 1993, is one of the leading nutrition companies in India. The firm focuses on developing and manufacturing across 3 verticals: Micronutrient Premix Products, Clinical Nutrition, and Therapeutic Foods. The company runs its 3 manufacturing facilities in India, located at Nasik, Chennai, and Thoothukudi, as well as an international facility in Tashkent, Uzbekistan. Its product portfolio is divided into 3 segments: Hexagon Nutrition sells its products across multiple channels, such as Retail medical stores/pharmacies, Hospitals, E-Commerce websites, Online Medicine Platforms, and through its own websites like Pentasure, Obesigo, Pediagold, and Nutrone. The company has 342 distributors in India and has exported to more than 75 countries in Asia, Africa, Europe, and South America.
Resources & Documents
Hexagon Nutrition Ltd., 404 Global Chamber, Adarsh Nagar Link Road, Andheri (W), Mumbai, Maharashtra, 400053
Hexagon Nutrition has set a price band of Rs 42–Rs 45 per share for an issue size of Rs 139 crore. The stock listed with a 7.22% gain versus its issue price on June 12, 2026.
Hexagon Nutrition Limited, founded in 1993, is one of the leading nutrition companies in India. The firm focuses on developing and manufacturing across 3 verticals: Micronutrient Premix Products, Clinical Nutrition, and Therapeutic Foods.
The issue is promoted by Arun Purushottam Kelkar, Subhash Purushottam Kelkar, Vikram Arun Kelkar and Nikhil Arun Kelkar with Cumulative Capital Pvt. Ltd., Catalyst Capital Partners Pvt. Ltd. acting as lead manager.
Grey market is quoting a premium of +Rs 6 (+13.3% over issue price), down Rs 4 from the previous session. Final subscription data records overall subscription at 53.48x, retail at 26.57x, QIB at 19.77x, NII at 161.21x.
On fundamentals, the company is posting revenue growth of 8.8%, a profit margin of 7.4%, return on equity of 12.5% in its most recent reported period. Listed peers in this segment include Zydus Wellness Limited (P/E 46.22x) and Nestlé India Limited (P/E 88.86x) — useful reference points when evaluating the issue's pricing relative to where the broader sector are trading.
Our data-driven engine currently flags this issue as a Subscribe call — the composite picture tilts favourable, though not without some caveats. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Understanding Grey Market Premium (GMP)
The Grey Market Premium (GMP) is an unofficial indicator of how an IPO's shares are trading in the grey market before they are officially listed on a stock exchange. It reflects investor sentiment and demand for the IPO shares ahead of listing day.
How does it work? The grey market is an informal, over-the-counter market where investors buy and sell IPO shares before the official listing date. If an IPO has a positive GMP, it suggests that investors expect the stock to list above its issue price. A negative GMP indicates expectations of a listing below the issue price.
Example: If an IPO has an issue price of ₹100 and the GMP is ₹50, the expected listing price would be approximately ₹150 (issue price + GMP). This translates to an estimated listing gain of 50%.
Factors that influence GMP:
- Subscription levels — Higher subscription typically drives GMP up
- Market conditions — Bullish markets tend to boost GMP across all IPOs
- Company fundamentals — Strong financials and growth potential attract premium
- Industry sentiment — Positive outlook for the sector can increase demand
- IPO pricing — Reasonably priced IPOs relative to peers tend to command higher GMP
Disclaimer: GMP is an unofficial metric from the grey market and is not regulated by SEBI or any stock exchange. GMP values fluctuate frequently and should not be the sole basis for investment decisions. Always consider company fundamentals, financial health, and your own risk appetite before investing in any IPO.
Related IPO
No comments yet. Be the first to share your opinion!